Two Drugs, One Pen: Who the Insulin and Semaglutide Combination Is Designed For

Introduction

If you already take a basal insulin and a GLP-1 medicine, your week probably involves two pens, two schedules, and a few reminders to keep everything straight. An insulin and semaglutide combination tries to shrink that routine into a single injection. The best-known version is IcoSema, which pairs insulin icodec with semaglutide. Let's look at what it is, who it was designed for, and what to check before you go further.

Insulin icodec is a basal insulin with a very long action, designed for use once a week. Semaglutide is a GLP-1 receptor agonist that is also given weekly. In the combined pen, both medicines come in a fixed proportion. This is not a new drug class. It is one device that carries two medicines that already exist in separate pens. If you want to follow how weekly GLP-1 products reach different markets, the weekly GLP-1 news coverage on OzemNews tracks these launches.

The practical reason for the design is simple: one application per week instead of two devices on different schedules. For someone who already manages two pens, that change alone can matter a lot.

Approval and launch status differ by country and change over time. Before you assume the product is available, check the current situation in the Anvisa registry, the European Medicines Agency database, and FDA's Drugs@FDA. A trial result describes what was studied. It does not replace a prescription.

How the two components work together

Basal insulin lowers fasting glucose. It provides a steady background level that covers the sugar the liver releases overnight and between meals. Semaglutide works differently. It slows stomach emptying, reduces appetite, and increases insulin secretion when glucose is high. Because the two act on different parts of the glucose picture, their effects complement each other rather than overlap. Insulin brings the baseline down, while semaglutide helps soften the rise after meals and reduces hunger.

Low blood sugar, or hypoglycemia, is the point that deserves the most attention. Insulin is the component most closely tied to dangerous lows. Labels for GLP-1 medicines also note that the risk of low blood sugar rises when they are used with insulin or sulfonylureas. As glucose improves, the insulin dose may need to come down. That is why regular glucose monitoring matters so much with this combination.

Dose adjustment follows steps set in the product label. The changes depend on measured glucose, usually fasting values, rather than on a fixed calendar. The exact thresholds and units belong to the label and to your prescriber, so read them carefully before making any change.

What the pivotal trials studied, and in whom

The phase 3 program for this combination is known as COMBINE. Its trials enrolled adults with type 2 diabetes. This post does not report trial numbers, durations, HbA1c reductions, weight changes, or hypoglycemia rates. Quoting figures from memory would be a mistake, so the original publications and registry records are the right place to look. Those sources list participant counts, study lengths, inclusion and exclusion criteria, and results for each arm. You can find the registered records by searching the program name on ClinicalTrials.gov.

Trial results describe averages in selected groups, and individual responses vary. Several groups were not the focus of the program. These include people with type 1 diabetes, pregnant people, and children and adolescents. There is little or no evidence to apply to them, so the combination should not be assumed to work or be safe in those groups.

Realistic clinical scenarios where it may fit

The combination may make sense in a few situations. Each one should be discussed with a clinician who knows the full history.

• A person already using basal insulin and a GLP-1 medicine in separate pens who wants to simplify the weekly routine.
• An adult with type 2 diabetes still above the glucose target on basal insulin alone, weighing options for next steps with their doctor.
• A person who finds it hard to keep up with several injections, where the burden of multiple devices affects adherence.
• A situation where the clinician considers body weight a secondary goal alongside glucose control.

Many people in these situations juggle two pens and two calendars, and keeping track of that routine is hard. Following how these routines change over time is part of what OzemNews covers, so readers can see how new options fit into everyday life. None of these scenarios replaces an individual evaluation.

The ADA Standards of Care 2025 recognize adding a GLP-1 receptor agonist to basal insulin as an option for some adults with type 2 diabetes who are above target. The Brazilian Diabetes Society (SBD) publishes its own guidance on this topic. Check the current edition of each document before applying it to a specific case.

Safety signals to explain without alarm

Hypoglycemia is the signal to know best. Symptoms can include shakiness, sweating, confusion, and a fast heartbeat. Treatment usually means a fast-acting sugar, such as juice or glucose tablets, followed by a glucose recheck. Agree on this plan in advance with your care team.

Gastrointestinal effects such as nausea, diarrhea, constipation, and vomiting are among the most common reports with GLP-1 medicines. They tend to be more noticeable when the dose goes up. A gradual titration schedule gives the body time to adjust.

GLP-1 medicines carry a boxed warning about thyroid C-cell tumors, which were seen in rodent studies. It is not known whether this risk occurs in humans. The medicine is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). The warnings also cover pancreatitis, and diabetic retinopathy complications in people with existing eye disease when blood sugar improves quickly. The speed of HbA1c improvement is part of the clinical follow-up for that reason. The product leaflet, or bula, is the document to read for the boxed warning and the warnings and precautions sections.

Practical questions: storage, access and checking the product

Storage rules depend on whether the pen has been opened. Unopened pens are usually kept in the refrigerator. Once in use, each pen has its own limits for room-temperature storage. Check the storage section of the bula for exact times, since they are set by the manufacturer and the regulator.

To confirm a product is legitimate in Brazil, look for the Anvisa registration number on the packaging and leaflet, confirm the manufacturer's name, and buy only through licensed pharmacies. The Anvisa medicine consultation portal lets you confirm that a product is registered. Keeping up with approvals and label changes on OzemNews can also help you spot updates before they reach the pharmacy shelf.

Coverage varies. Check whether the product appears on your health plan's formulary. For the public system, the Conitec reports show whether a technology has been incorporated into the SUS or is still under review. The CMED list publishes regulated maximum prices, which helps when comparing one combined pen with two separate pens. Note the date of each query, because lists are updated.

When you prepare for a visit, bring a log of glucose readings, the current doses of each medicine, and any low episodes. Questions about titration, insulin adjustment, and how often to check glucose will make the conversation more useful.

FAQ

Is the insulin and semaglutide combination the same as using both pens?

The two medicines are the same molecules, but they come in one pen with a fixed proportion. The main practical difference is one injection per week instead of two. Dosing still follows the product label and your clinician's plan.

Is the combination available in Brazil?

Availability depends on current approval by Anvisa, which can change over time. Search the Anvisa registry for the current status, and do not assume a product is available just because it has been approved elsewhere.

Can the combination cause low blood sugar?

Yes. Hypoglycemia is the main safety point, especially because insulin is part of the product. Glucose monitoring and a plan for treating lows are essential parts of using it safely.

Is the combination meant for weight loss?

Semaglutide can affect body weight, and weight was a secondary outcome in the trials. The combination was studied in adults with type 2 diabetes, so its main purpose is glucose control. Weight decisions belong to the clinician and the individual case.

Can people with type 1 diabetes use it?

The combination was not the focus of the program in type 1 diabetes, so there is little or no evidence supporting that use. Any decision about diabetes treatment should be made with a specialist.

Sources

• Anvisa - Consulta de medicamentos (registros e bulas)
• European Medicines Agency - Medicines (EPAR e informações de produto)
• U.S. FDA - Drugs@FDA (aprovações e rótulos)
• ClinicalTrials.gov - Busca pelo programa de estudos de insulina icodeca e semaglutida (COMBINE)
• American Diabetes Association - Standards of Care in Diabetes 2025, Diabetes Care vol. 48, suppl. 1
• Sociedade Brasileira de Diabetes (SBD)
• Conitec - Comissão Nacional de Incorporação de Tecnologias no SUS
• CMED - Câmara de Regulação do Mercado de Medicamentos (lista de preços)